HopeStage
Back to all studies
CompletedNCT03292146

Denosumab, Alendronate or Placebo for Bone Health in Women With Anorexia

About this title

Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

Read the official source — NCT03292146
Medication studyAges 20–60United StatesEating disorders
The study in practice

Understand this study

Who was this study for?

Listed age limits: 20 years to 60 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 25, 2017
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 20 Years to 60 Years
Official registry ID
NCT03292146
Official title
Show the full official title

Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Denosumab 60 MG [Prolia], Placebo Injection and Alendronate 70Mg Tab.

Who was this study for?

Listed age limits: 20 years to 60 years.

Want to explore more studies?

Explore studies